IBO vs GILD

Gilead Sciences, Inc.

(GILD) offers the better valuation at 358. 7x trailing P/E (15. 9x forward), making it the more compelling value choice. Analysts rate Gilead Sciences, Inc. (GILD) a "Buy" — based on 58 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +127. 5%, compared to -99. 8% for Impact BioMedical Inc. (IBO). Over 10 years, the gap is even starker: GILD returned +92. 6% versus IBO's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Impact BioMedical Inc.

(IBO) is the lower-risk stock at 0. 12β versus Gilead Sciences, Inc. 's 0. 66β — meaning GILD is approximately 427% more volatile than IBO relative to the S&P 500. On balance sheet safety, Impact BioMedical Inc. (IBO) carries a lower debt/equity ratio of 123% versus 139% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Impact BioMedical Inc.

grew EPS 0. 0% year-over-year, compared to -91. 6% for Gilead Sciences, Inc.. Over a 3-year CAGR, IBO leads at 259. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 1. 7% net margin versus -88. 0% for Impact BioMedical Inc. — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IBO leads at 23. 7% versus 5. 8% for GILD. At the gross margin level — before operating expenses — IBO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, GILD (2.

3% yield) pays a dividend. IBO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Gilead Sciences, Inc.

(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 2. 3% yield). Both have compounded well over 10 years (GILD: +92. 6%, IBO: -97. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

GILD pays a dividend while IBO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.